Fintech PR
Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline
MELBOURNE, Australia, Feb. 22, 2024 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its results for the financial year ended 31 December 2023. All figures are in AUD$ unless otherwise stated.[1]
2023 highlights
- Total Group revenue of $502.5M, an increase of 214% from $160.1M in 2022 primarily driven by continued strong growth in sales of Illuccix® in the second year since commercial launch (April 2022)
- Delivered positive adjusted earnings before interest, tax, depreciation, and amortisation (adjusted EBITDA) of $58.4M an increase of $126.2M, compared to a loss of $67.8M in 2022
- Inaugural full year profit of $5.2M after tax. A substantial improvement on the net loss after tax of $104.1M in 2022
- Investment in research and development (R&D) and selling, general and administration (SG&A) reflects progress across the late-stage pipeline and scale-up of the commercial organisation
- Overall operating costs as a percentage of revenue have reduced to 52% from 105% in 2022
- Gross margin has improved to 63% (vs. 59% in 2022) reflecting distribution and manufacturing costs optimisation
- Positive operating cash inflow in line with commercial sales growth, demonstrated through customer receipts of $463.7M (vs. $124.1M in 2022), and
- Closing cash balance was $123.2M as at 31 December 2023.
Progress across the core pipeline includes:
- First patients dosed in the ProstACT GLOBAL Phase III clinical trial of TLX591, a first-in-class investigational rADC[2] for prostate cancer therapy
- Positive interim readout from the ProstACT SELECT Phase I clinical trial reinforcing the differentiation of TLX591, including favourable safety profile and clinical utility of the patient-friendly short dosing regimen
- Submission of the Biologics License Application (BLA) for TLX250-CDx (Zircaix™[3]) to the United States Food and Drug Administration (U.S. FDA) for kidney cancer imaging on a rolling review basis
- Patients dosed in multiple clinical trials of Telix’s therapeutic candidate TLX250 for clear cell renal cell carcinoma (ccRCC) and other solid tumours expressing carbonic anhydrase IX (CAIX)
- First cohort of patients dosed in the IPAX-2 trial investigating Telix’s glioblastoma therapy candidate, TLX101, in newly diagnosed patients
- Commercialisation plans underway for glioma imaging agent, TLX101-CDx (Pixclara™[3]), ahead of the planned submission of a New Drug Application (NDA) to the U.S. FDA in Q1 2024, and
- Ethics approval granted to commence biodistribution and safety study of TLX300-CDx, first human study of radiolabelled olaratumab being developed as a therapeutic candidate for soft-tissue sarcoma.
Dr Christian Behrenbruch, Managing Director and Group CEO commented:
“This is an excellent result which demonstrates the strength of the Telix business model. We have achieved profitability while intensively investing in the development of our late-stage assets and the scale-up of our commercial infrastructure and marketing activity. This has resulted in Telix capturing a meaningful market share in the growing urology imaging market whilst laying the foundation for our next commercial products.
“We are highly focused on the development of our theranostic pipeline and vertical integration of supply and manufacturing. This activity is key to diversifying our revenue streams, creates additional value for our therapeutic assets and further differentiates Telix as a fully integrated global radiopharmaceutical company.”
Further details on the Company’s results can be found in the Appendix 4E, the accompanying investor presentation, and 2023 Annual Report lodged with the ASX and also available on the Company’s website.
Guidance
Full year revenue for 2024 expected range of US$445M to US$465M ($675M to $705M at current exchange rates), representing an approximate 35-40% increase on 2023.
Revenue guidance is based on worldwide sales of Illuccix®, with potential upside from Zircaix™[3] (kidney cancer imaging) and Pixclara™[3] (glioma imaging), subject to product regulatory approvals. Guidance will be updated throughout the year, as appropriate, to reflect product approvals.
Expected additional investment of 40-50% in R&D (compared with 2023), including both external and internal costs funded by operating cash flow and broadly in line with revenue growth.
2024 R&D investment activity is expected to include validation of commercial manufacturing and market launch activities in preparation for approval of Zircaix™[3] and Pixclara™[3] a fully operationalised ProstACT GLOBAL therapy trial in prostate cancer, and initiation of additional therapeutic clinical trials, including manufacturing activity, across the broader pipeline. 2024 R&D investment also includes indication expansion and life-cycle management of Illuccix®.
Investor call
An investor webcast will be held at 9.00am AEDT on Friday 23 February 2024 (Thursday 22 February 2024, 5.00pm EST)
Participants can register for the webcast and find audio call details at the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=Y7PkfQhS
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn.
Telix’s lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA),[4] by the Australian Therapeutic Goods Administration (TGA),[5] and by Health Canada.[6] Telix’s miniaturised surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, has attained a marketing authorisation in the U.S., having been registered with the FDA and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area for the intra-operative detection of sentinel lymph nodes (SLNs). With the exception of Illuccix® and SENSEI® as noted above, no Telix product has received a marketing authorisation in any jurisdiction.
Full United States prescribing information for Illuccix® can be found at: http://illuccixhcp.com/s/illuccix-prescribing-information.pdf
Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: [email protected]
This announcement including earnings guidance has been authorised for release by the Telix Pharmaceuticals Limited Board.
Legal Notices
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this announcement. The information contained in this announcement is subject to change without notification.
This announcement may contain forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website.
To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.
Telix uses various non-IFRS information to reflect its underlying performance. For further information, the reconciliation of non-IFRS financial information to Telix’s statutory measures, reasons for usefulness and calculation methodology, please refer to the Alternative performance measures section in Telix’s Annual Report.
©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix®, Pixclara™,[3] Zircaix™[3] and SENSEI® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
|
[1] Conversion to AUD$ is at the exchange rate on the relevant transaction date. The average exchange rate realised during the period was AUD$1 = US$0.66; AUD$1 = €0.54. |
|
[2] Radio antibody-drug conjugate. |
|
[3] Trade name subject to final regulatory approval. |
|
[4] Telix ASX disclosure 20 December 2021. |
|
[5] Telix ASX disclosure 2 November 2021. |
|
[6] Telix ASX disclosure 14 October 2022. |
Logo – https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/telix-2023-full-year-results-inaugural-profit-achieved-strong-revenue-growth-underpins-investment-in-late-stage-pipeline-302068547.html
LONDON, Nov. 26, 2024 /PRNewswire/ — Hakluyt, the global strategic advisory firm for businesses and investors, has today announced a new social impact partnership with Orchestras for All (OFA), on the eve of the charity’s Big Give Campaign launch.
Orchestras for All is a UK-based charity that works with 11-19 year-olds to widen access to music, with a particular focus on those who face challenges such as disability, deprivation or caring responsibilities.
Drawing on its connectivity and in-house expertise, Hakluyt will advise the charity on issues as it seeks to fulfil its mission to ensure that all children, regardless of background or circumstance, are able to share in the benefits of group music-making.
Hakluyt, which has been providing in-kind support to the charity since 2022, has now formalised a partnership with Orchestras for All that will see it provide advice and guidance across a range of strategic challenges in order to help the charity widen its impact and reach more young people.
Kayo Yoshida, who co-leads Hakluyt’s work with Orchestras for All, said: “Orchestras for All does invaluable work sharing the benefits of music with children who have often been shut out of creative opportunities. I am personally delighted to be working with them, and look forward to our partnership flourishing over the coming years.”
Alexandra Davison, who also co-leads Hakluyt’s work with the charity, commented: “The opportunities that Orchestras for All offers can be life-changing for young people. The myriad benefits of musical education to children’s development and educational attainment are well known, and Orchestras for All is an organisation with a proven track record of widening access to music for the children who need it most.”
Nick Thorne, Executive Director of Orchestras for All, added: “We are delighted to have formalised our partnership with Hakluyt, and are incredibly grateful for the support they provide. This relationship is one of our most significant corporate partnerships to date, offering both financial support and advisory services.
“The funding Hakluyt have provided will not only help OFA continue providing its life-changing musical programmes, but also enable our participation in the Big Give Christmas Challenge 2024. Through this campaign, OFA aims to raise vital funds to ensure that more young people can access inclusive and transformative music-making opportunities.”
Notes to Editors
Hakluyt is a strategic advisory firm that works with corporate leaders and investors around the world on their most important commercial issues. For more information on the firm, please visit www.hakluytandco.com
Orchestras for All (OFA) is an Arts Council National Portfolio Organisation that breaks down barriers to give all young people the life-changing experience of making music together, regardless of the daily challenges they might be facing. Its inclusive, non-auditioned National Orchestra for All (NOFA) brings together 100 young musicians from across the UK who would otherwise be unable to access musical opportunities – whether due to physical disability, a mental health condition, economic deprivation, or rural isolation.
View original content:https://www.prnewswire.co.uk/news-releases/hakluyt-announces-new-partnership-with-orchestras-for-all-302316677.html
Fintech PR
MarketsandMarkets appoints Nirmal Shani as Managing Partner in Dubai, in line with IPO plans
DELRAY BEACH, Fla., Nov. 26, 2024 /PRNewswire/ — MarketsandMarkets, the only Indian-origin startup to feature in the Forbes list of ‘America’s Best Management Consulting Firms 2023’, has appointed Nirmal Ramesh Shani as Managing Partner.
Nirmal joins MarketsandMarkets from S&P Global to lead its real-time megatrend disruption impact platform for the global energy sector. He has over 23 years of experience with IHS Markit, Dun & Bradstreet, and Times of India. During his formative years, he supported his family business, exporting Indian handicrafts to Japan and USA.
Sandeep Sugla, Founder and CEO of MarketsandMarkets, said: “It’s my pleasure to welcome Nirmal to MarketsandMarkets. His leadership further strengthens our ability to address customer needs at a time when the global energy, power, chemical, material, and industrial sectors are undergoing unprecedented transformations. We estimate approximately USD 25 trillion emerging from new revenue sources by 2030 as megatrends like AI, clean tech, blockchain, IoT, etc., disrupt current revenue streams of customers and the customer’s customers.”
Milan Rao, COO and CRO of MarketsandMarkets, said, “Nirmal joins a growing list of global leaders who are committed to taking our AI-enabled platform, KnowledgeStore, and our cutting-edge growth and disruption consulting capabilities to over 13,000 clients globally. His knowledge and expertise will add significantly to our presence in the energy and ESG sectors worldwide.”
Nirmal is passionate about energy and sustainability; in his most recent role at S&P Global, he helped create landmark platforms — such as the CERAWeek Asia Pacific Energy Forum in Houston, the India Energy Forum in New Delhi, the partnership with PETRONAS for Energy Asia in Kuala Lumpur, and with Japan’s Ministry of Economy, Trade and Industry (METI) for the Asia Green Growth Partnership Ministerial Meeting (AGGPM) — to elevate the Voice of Asia within the global energy system towards an ‘Equitable Energy Transition for All’.
On his appointment, Nirmal said: “MarketsandMarkets helps progress my mission to the next level. I haven’t seen any other platform in the world that provides such a telescope for global energy, chemical, and industrial leaders to analyze the impact of disruptive shifts in real-time and in an interconnected way. The proprietary tools combined with exclusive on-demand access to research, and a dedicated growth program manager ensures our clients avoid missing blind spots and gain early mover advantages.”
Nirmal is an alum of Narsee Monjee College and Welingkar Institute of Management. He serves on the Board of Advisors/Governing Council of Umang Foundation, a non-profit organization with whom he has been associated since 2009. His philanthropic initiatives focus on education and health-related issues in rural India.
About MarketsandMarketsTM
MarketsandMarkets™, recently featured on the Forbes list of America’s Best Management Consulting Firms, is a blue ocean alternative in growth consulting and program management with the widest lens on emerging technologies, leveraged through a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. The B2B economy is witnessing the emergence of USD 25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. MarketsandMarkets™ works with several Forbes Global 2000 B2B companies, helping them monetize this USD 25 trillion opportunity—through TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing—and stay relevant in a disruptive ecosystem. MarketsandMarkets’ cutting-edge AI-powered KnowledgeStore™ platform (Market Intelligence Cloud) integrates research and facilitates analyses of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To learn more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn, and Facebook.
Media inquiries:
Mr. Rohan Salgarkar
USA: +1-888-600-6441
Photo: https://mma.prnewswire.com/media/2567625/Nirmal_Shani_MarketsandMarkets.jpg
Photo: https://mma.prnewswire.com/media/2567576/Aman_Sandeep_Nirmal_MarketsandMarkets.jpg
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original content:https://www.prnewswire.co.uk/news-releases/marketsandmarkets-appoints-nirmal-shani-as-managing-partner-in-dubai-in-line-with-ipo-plans-302316430.html
Fintech PR
StarCompliance Expands Cryptocurrency Compliance Capabilities with the Acquisition of Aer Compliance
Bringing traditional securities trading compliance and digital asset management into one comprehensive solution
ROCKVILLE, Md., Nov. 26, 2024 /PRNewswire/ — StarCompliance (Star), a leading SaaS provider of employee compliance technology solutions, is excited to announce the acquisition of Argus Inc. DBA Aer Compliance (Aer), a leader in cryptocurrency trading pre-clearance and post-trade monitoring solutions. This strategic acquisition positions Star clients to monitor and mitigate risk more holistically by bringing traditional securities trading, and now digital assets, into one comprehensive solution. With Aer’s unique capability to monitor at the coin and wallet level—going beyond ETFs— Star’s clients will gain unparalleled visibility and control in the rapidly evolving cryptocurrency landscape.
“By integrating Aer’s advanced technology into our platform, Star is helping our clients prepare and get ahead of emerging regulations in the fast-changing cryptocurrency space,” said Jennifer Sun, CEO of Star. “We’ve been very fortunate to work with Owen and his team over the last 18 months as partners and now look forward to our future as a combined company.”
Owen Rapaport, Aer’s co-founder and CEO, will join Star as Executive Director of Product Management, Digital Assets, continuing to develop, integrate and introduce innovative solutions for mitigating cryptocurrency and digital asset risk. This acquisition builds on Star’s leadership position in regulatory compliance, adding advanced tools to Star’s Employee Conflicts of Interest suite, tailored to the rapidly evolving world of digital assets, ensuring clients stay ahead of emerging regulatory requirements.
The Aer acquisition adds several capabilities to Star’s robust offerings, including:
- Configurable, automated employee pre-trade clearance, post trade monitoring and automated alerts for digital assets
- Elimination of manual trade reviews with the ability to identify potential violations with post-trade monitoring across 130+ exchanges and 30+ blockchains
- Recognition of undeclared employee accounts using public blockchain data
- AI technology enabling assisted reviews of marketing content for unsubstantiated statements of material facts and hypothetical performance leading to faster approvals.
“As cryptocurrency continues to mature both as a personal investment asset class and a strategic business line for financial institutions, the demand for robust compliance solutions has never been greater,” said Rapaport. “Star’s vision for advancing employee compliance aligns perfectly with Aer’s commitment to fostering trust and integrity in this evolving landscape. Together, we will deliver cutting-edge products and usher in a new era of cryptocurrency trading and compliance.”
About Aer Compliance
Aer Compliance (Aer), incorporated in Delaware as Argus Inc., is the first employee trade compliance solution for digital assets. With a customer base comprising the largest funds and market makers globally, Aer’s software brings robust controls to this world of emerging risks. As regulators increase their scrutiny of cryptocurrency, Aer is the essential way to ensure appropriate measures are in place to protect both the firm and its employees. Aer’s US federal public sector work further informs its cutting-edge approach to compliance. You can find out more about the solution at www.aercompliance.com.
About StarCompliance
StarCompliance (Star) is a leading provider of employee compliance technology solutions. Trusted for over 25 years by over a million users in 114 countries, Star’s next-generation platform and user-friendly interface delivers the data, technology, and actionable insights needed to proactively mitigate risk, monitor conflicts globally, and support complex whistleblowing regulations. Visit www.starcompliance.com to discover the comprehensive security and unparalleled assurance you need to build a culture of compliance today.
Media Contact:
Greg Tarmin
+1 917-868-7791
[email protected]
View original content:https://www.prnewswire.co.uk/news-releases/starcompliance-expands-cryptocurrency-compliance-capabilities-with-the-acquisition-of-aer-compliance-302316262.html
-
Fintech6 days agoFintech Pulse: Industry Updates, Innovations, and Strategic Moves
-
Fintech5 days agoFintech Pulse: Daily Industry Brief – A Dive into Today’s Emerging Trends and Innovations
-
Fintech PR6 days agoTAILG Represents the Industry at COP29, Advancing South-South Cooperation with Low-Carbon Solutions
-
Fintech PR6 days agoROLLER Releases 2025 Attractions Industry Benchmark Report, Unveiling Key Trends and Revenue Strategies
-
Fintech7 days agoFintech Pulse: Milestones, Partnerships, and Transformations in Fintech
-
Fintech PR4 days agoAlkira Ranked 25th Fastest-Growing Company in North America and 6th in the Bay Area on the 2024 Deloitte Technology Fast 500™
-
Fintech PR6 days agoThe CfC St. Moritz Announces New Speakers from BlackRock, Binance, Bpifrance, Temasek, PayPal, and More for Upcoming 2025 Conference
-
Fintech PR4 days agoCorinex Ranked Number 331 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™